Literature DB >> 32186962

Dissociation of Pubertal Development Abnormality and Gonadal Dysfunction in Childhood Cancer Survivors.

Bo Yu1, Rani Fritz2, Mario Vega2, Margret Merino3.   

Abstract

Purpose: To determine the relationship between pubertal development and postpubertal gonadal function in childhood cancer survivors.
Methods: Childhood cancer survivors (≥10 years of age) who received follow-up care in a pediatric oncology group in an academic medical center during the period from January 1, 1985, to July 1, 2010 were included in this case series. Their pubertal development and gonadal function were evaluated.
Results: The cohort consists of 39 males (age 10-21 years) and 35 females (age 10-29 years) with a variety of cancer diagnosis and treatments. The average age at diagnosis was ∼7.5 years. The average age at the time of the study was 16 and 16.7 years in males and females, respectively, representing a mean follow-up interval of ∼9 years. Despite the fact that 60% of survivors received cyclophosphamide equivalents and 16.2% received cranial radiation or brain tumor resection, the majority of survivors (68%) presented with both normal puberty and normal gonadal functions at the time of follow-up. In 27% of survivors, puberty development did not predict gonadal function in early adulthood: 20% of survivors had normal puberty, but abnormal gonadal function; 7% of survivors had abnormal puberty, but gonadal function remained normal as young adults. Conclusions: Most childhood cancer survivors had normal puberty and gonadal function despite a variety of cancer treatment modalities. However, normal puberty did not predict normal gonadal function later in life in many survivors. Therefore, close follow-up with gonadal function in adolescent and early adulthood years is essential.

Entities:  

Keywords:  chemotherapy; childhood cancer survivor; gonadal function; premature ovarian insufficiency; puberty; radiation therapy

Mesh:

Year:  2020        PMID: 32186962      PMCID: PMC7415869          DOI: 10.1089/jayao.2019.0138

Source DB:  PubMed          Journal:  J Adolesc Young Adult Oncol        ISSN: 2156-5333            Impact factor:   2.223


  25 in total

Review 1.  Endocrine complications in long-term survivors of childhood cancers.

Authors:  Wassim Chemaitilly; Charles A Sklar
Journal:  Endocr Relat Cancer       Date:  2010-06-03       Impact factor: 5.678

Review 2.  Hypothalamic-Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline.

Authors:  Charles A Sklar; Zoltan Antal; Wassim Chemaitilly; Laurie E Cohen; Cecilia Follin; Lillian R Meacham; M Hassan Murad
Journal:  J Clin Endocrinol Metab       Date:  2018-08-01       Impact factor: 5.958

Review 3.  Endocrine Late Effects in Childhood Cancer Survivors.

Authors:  Wassim Chemaitilly; Laurie E Cohen; Sogol Mostoufi-Moab; Briana C Patterson; Jill H Simmons; Lillian R Meacham; Hanneke M van Santen; Charles A Sklar
Journal:  J Clin Oncol       Date:  2018-06-06       Impact factor: 44.544

Review 4.  Alterations in pubertal timing following therapy for childhood malignancies.

Authors:  Gregory T Armstrong; Eric J Chow; Charles A Sklar
Journal:  Endocr Dev       Date:  2009-03-03

Review 5.  Chemotherapy and amenorrhea: risks and treatment options.

Authors:  Kutluk Oktay; Murat Sönmezer
Journal:  Curr Opin Obstet Gynecol       Date:  2008-08       Impact factor: 1.927

6.  Fertility of male survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.

Authors:  Daniel M Green; Toana Kawashima; Marilyn Stovall; Wendy Leisenring; Charles A Sklar; Ann C Mertens; Sarah S Donaldson; Julianne Byrne; Leslie L Robison
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

7.  Ovarian function after autologous bone marrow transplantation in childhood: high-dose busulfan is a major cause of ovarian failure.

Authors:  C Teinturier; O Hartmann; D Valteau-Couanet; E Benhamou; P F Bougneres
Journal:  Bone Marrow Transplant       Date:  1998-11       Impact factor: 5.483

8.  Parenthood probability and pregnancy outcome in patients with a cancer diagnosis during adolescence and young adulthood.

Authors:  H Magelssen; K K Melve; R Skjaerven; S D Fosså
Journal:  Hum Reprod       Date:  2007-11-16       Impact factor: 6.918

9.  The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the Childhood Cancer Survivor Study.

Authors:  Daniel M Green; Vikki G Nolan; Pamela J Goodman; John A Whitton; DeoKumar Srivastava; Wendy M Leisenring; Joseph P Neglia; Charles A Sklar; Sue C Kaste; Melissa M Hudson; Lisa R Diller; Marilyn Stovall; Sarah S Donaldson; Leslie L Robison
Journal:  Pediatr Blood Cancer       Date:  2013-08-12       Impact factor: 3.167

10.  Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer.

Authors:  H Koyama; T Wada; Y Nishizawa; T Iwanaga; Y Aoki
Journal:  Cancer       Date:  1977-04       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.